Vancomycin and Renal Function in a Canine Patient
A 6-year-old male neutered Labrador Retriever (32 kg) is hospitalized with a deep surgical site infection following TPLO. Culture grows methicillin-resistant Staphylococcus pseudintermedius susceptible only to vancomycin and chloramphenicol. The surgeon requests IV vancomycin. Baseline labs: creatinine 1.4 mg/dL (reference 0.5–1.6), BUN 22 mg/dL, urine specific gravity 1.030, no proteinuria. The dog is receiving carprofen 2.2 mg/kg PO q12h for postoperative pain, omeprazole, and enrofloxacin (to which the organism is resistant). The pharmacy stocks vancomycin 500 mg vials and reports a trough target of 5–10 mcg/mL for staphylococcal infections. The technician asks whether the concurrent medications matter and how to time levels.
1. Identify the drug-interaction and monitoring concerns you would raise before approving vancomycin, and explain the pharmacologic basis for each.
Read the worked answer
NSAID + vancomycin (nephrotoxicity stacking). Carprofen reduces renal prostaglandin-mediated afferent arteriolar dilation; vancomycin causes dose- and exposure-related tubular injury. Together the risk of acute kidney injury is additive. The creatinine of 1.4 is within reference but at the upper end for a 32 kg dog; a single normal value does not exclude reduced GFR. Consider switching analgesia to an opioid (e.g., buprenorphine or methadone) for the duration of vancomycin therapy rather than continuing the NSAID.
Enrofloxacin is irrelevant to therapy. The isolate is resistant, so continuing it adds adverse-effect risk (particularly retinal and cartilaginous concerns with fluoroquinolones) without benefit. Discontinue and document the reason.
Omeprazole is not a major vancomycin interaction but acid suppression alters GI flora and may modestly affect oral absorption-irrelevant here since the route is IV.
Monitoring: baseline CBC, chemistry panel, and urinalysis are appropriate; recheck creatinine and urinalysis every 24–48 h during therapy. Trough sampling should occur within 30 min before the next dose, after steady state (roughly 4–5 half-lives). Because vancomycin is renally eliminated almost entirely by glomerular filtration, any rise in creatinine mandates dose-interval extension rather than dose reduction alone.
2. The pharmacy proposes 15 mg/kg IV q12h. Critique this regimen for this patient and describe how you would adjust it if creatinine rises to 2.8 mg/dL on day 3.
Read the worked answer
Critique of 15 mg/kg q12h. For MRSP, human and veterinary consensus targets troughs of roughly 5–10 mcg/mL (some sources 10–15 for deep infection) with AUC-guided monitoring preferred where available. 15 mg/kg q12h is a reasonable starting point in a dog with normal renal function, but two caveats apply:
The patient's renal reserve is unproven. A creatinine of 1.4 with concentrated urine in a postoperative dog may reflect prerenal azotemia or early injury. Starting at the lower end (e.g., 12–15 mg/kg) with a planned trough before the third dose is prudent.
Infusion rate matters. Vancomycin should be infused over at least 60 minutes (some recommend 60–90 min) to limit histamine-mediated reactions ('red man' type) and peak-related nephrotoxicity. A rapid push is inappropriate.
If creatinine rises to 2.8 mg/dL (roughly doubled): this represents substantial reduction in GFR. Do not simply halve the dose-extend the interval. Estimate the new elimination half-life from the creatinine change (approximately proportional to the rise in creatinine if renal function is the sole determinant), giving an interval of roughly q24h, and recheck a trough before the next dose. Hold the next dose until a trough is obtained if there is any concern for accumulation. Reassess the necessity of continued vancomycin versus an alternative (chloramphenicol is susceptible per culture but carries human aplastic-anemia handling concerns and is bacteriostatic). Document the interaction with carprofen as a probable contributor and discontinue the NSAID.